The Alzheimer's disease neuroimaging initiative.

  title={The Alzheimer's disease neuroimaging initiative.},
  author={Susanne G. Mueller and Michael W Weiner and Leon Thal and Ronald C. Petersen and Clifford R. Jack and William J. Jagust and John Q. Trojanowski and Arthur W. Toga and Laurel A Beckett},
  journal={Neuroimaging clinics of North America},
  volume={15 4},
          869-77, xi-xii

The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes

Imaging and Biomarkers in Early Alzheimer's Disease and Mild Cognitive Impairment

It is likely that the use of a combination of neuroimaging and chemical biomarkers will be involved in predicting the development of dementia and Alzheimer's disease (AD).


A growing body of knowledge regarding amyloid and tau neuropathology, genetic susceptibility, genetic and environmental risk modifiers, early and atypical clinical presentations, and the use of symptom-modifying medical and psychosocial therapies is available to aid in the diagnosis and management of patients with AD.

Q & A: The Alzheimer's disease neuroimaging initiative

  • P. Aisen
  • Biology, Psychology
    BMC medicine
  • 2011
A large, highly collaborative longitudinal cohort study aiming to elucidate biomarker trajectories in Alzheimer’s disease (AD) and the large cost and effort required to conduct appropriate studies.

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease

The Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to

Neuroimaging biomarkers in Alzheimer’s disease

Review Articles The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans

Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects, and ADNI provides significant new information concerning the progression of AD.

Differences in Medication Use in the Alzheimer’s Disease Neuroimaging Initiative

Differences in the frequency of symptomatic treatment were observed as a function of age, years of education, gender and disease severity, and many were also taking one or more medications with the potential for adverse effects.



Pathology and Pathways of Alzheimer's Disease with an Update on New Developments in Treatment

  • S. DeKosky
  • Psychology, Biology
    Journal of the American Geriatrics Society
  • 2003
The current understanding of the course and pathology of Alzheimer's disease as it relates to emerging therapies is reviewed, then some promising current research directions in primary prevention, secondary prevention, and treatment are summarized.

CSF biomarkers for mild cognitive impairment

  • K. Blennow
  • Medicine, Biology
    Journal of internal medicine
  • 2004
There is a great clinical need for diagnostic biomarkers to identify incipient AD in MCI cases and three cerebrospinal fluid biomarkers; total‐tau (T‐τ), phospho‐t Tau (P‐τ) and the 42 amino acid form of β‐amyloid (Aβ42) have been evaluated in numerous scientific papers.

Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders

Early detection of neurodegenerative disorders would provide clues to the underlying pathobiology of these diseases and would enable more effective diagnosis and treatment of patients and, ultimately, of disease-modifying medications for use early in disease and during the presymptomatic period.

Mild cognitive impairment as a diagnostic entity

  • R. Petersen
  • Psychology, Medicine
    Journal of internal medicine
  • 2004
It is suggested that the diagnosis of mild cognitive impairment can be made in a fashion similar to the clinical diagnoses of dementia and AD, and an algorithm is presented to assist the clinician in identifying subjects and subclassifying them into the various types of MCI.

Alzheimer's disease – do tauists and baptists finally shake hands?

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

Levels of isoprostane 8,12-iso-iPF(2alpha)-VI found in cerebrospinal fluid, plasma, and urine of subjects with MCI imply that individuals withMCI have increased brain oxidative damage before the onset of symptomatic dementia.

The neuropathology of dementia

The clinical features and neuroanatomical basis of dementia, and the practical approach to the pathological diagnosis of dementia: important anatomical landmarks in the brain in dementia, are defined.

Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

A multidisciplinary, international group of experts discussed the current status and future directions of MCI, with regard to clinical presentation, cognitive and functional assessment, and the role of neuroimaging, biomarkers and genetics.

Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia

To determine whether automatic and manual measurements of hippocampal volume differences on MRI between normal aging, cognitive impairment (CI), and Alzheimer's disease (AD) yield similar results, an attempt is made to compare the results of manual and automatic measurements.